Key result
Ticagrelor- and clopidogrel-based DAPT show unstated comparative outcomes in cerebral endovascular procedures.
Why the study?
The safety and efficacy outcomes of ticagrelor- versus clopidogrel-based dual antiplatelet therapy in patients undergoing cerebral endovascular procedures were not well established in a large, real-world setting.
Does ticagrelor-based dual antiplatelet therapy improve safety and efficacy outcomes compared to clopidogrel-based dual antiplatelet therapy in patients undergoing cerebral endovascular procedures?
Does ticagrelor-based dual antiplatelet therapy improve safety and efficacy outcomes compared to clopidogrel-based dual antiplatelet therapy in patients undergoing cerebral endovascular procedures?
Answers are grounded in this paper and cite their sources.
Retrospective cohort study reports safety and efficacy of ticagrelor versus clopidogrel in cerebral endovascular procedures, highlighting optimal antiplatelet selection.
To assess and compare the safety and efficacy outcomes of ticagrelor-versus clopidogrel-based dual antiplatelet therapy in patients undergoing cerebral endovascular procedures using a large, real-world, propensity score–matched cohort.
No takes yet. Share an insight, caveat, or question.
Coelho et al. (2026) studied this question. Ticagrelor- and clopidogrel-based dual antiplatelet therapies were compared for safety and efficacy in cerebral endovascular procedures, but the abstract provides no results.
Synapse has enriched 10 related papers. Consider them for comparative context: